Chemtrade Logistics Income Fund (CGIFF) — Earnings Call X-Ray
Our AI read all 31 of CGIFF's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
D
Q4 2024
Calls Analyzed
31
2016–2025
Avg Candor
7.2/9
evasion 2.8/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-13
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of CGIFF's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
D
Q4 2024 earnings call
2025-02-28
move ±7.7%
Management gave no formal guidance. The delivery was light on specifics, relaxed under questioning.
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedCFO dominates
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
B
Q3 2024 earnings call
2024-11-15
move ±8.6%
Management raised guidance against steady demand. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: stableMargins: stablePricing: raisingCapex: decreasing 5 analysts · 14 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B+
Q2 2024 earnings call
2024-08-15
move ±8.6%
Management raised guidance against steady demand and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: stableMargins: expandingPricing: raisingHeadcount: cuttingCapex: increasing 6 analysts · 15 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B
Q1 2024 earnings call
2024-05-16
move ±7.1%
Management raised guidance against steady demand. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: stableMargins: stablePricing: stableCapex: increasing 6 analysts · 17 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
YES Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q4 2023 earnings call
2024-02-21
move ±9%
Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: mixedMargins: contractingPricing: under pressureCapex: increasing 6 analysts · 21 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubtsDirection beats results
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C+
Q3 2023 earnings call
2023-11-15
move ±10.2%
Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: mixedMargins: expandingPricing: under pressureCapex: increasing 4 analysts · 12 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedCFO dominates
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
A
Q2 2023 earnings call
2023-08-15
move ±14.5%
Management raised guidance against mixed demand signals and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: raisedDemand: mixedMargins: expandingPricing: raisingCapex: decreasing 7 analysts · 23 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
YES Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q1 2023 |
2023-05-12 |
B+ |
raised | mixed | expanding |
7/9 |
3/9 |
| Q4 2022 |
2023-02-25 |
C+ |
maintained | stable | stable |
7/9 |
3/9 |
| Q3 2022 |
2022-11-12 |
B+ |
raised | accelerating | expanding |
7/9 |
3/9 |
| Q2 2022 |
2022-08-11 |
B+ |
raised | accelerating | expanding |
7/9 |
3/9 |
| Q1 2022 |
2022-05-10 |
B+ |
raised | accelerating | expanding |
7/9 |
3/9 |
| Q4 2021 |
2022-02-23 |
C |
maintained | mixed | contracting |
7/9 |
6/9 |
| Q3 2021 |
2021-11-11 |
B |
maintained | accelerating | mixed |
7/9 |
2/9 |
| Q2 2021 |
2021-08-12 |
C+ |
maintained | accelerating | contracting |
7/9 |
3/9 |
| Q1 2021 |
2021-05-11 |
D |
withdrawn | mixed | contracting |
7/9 |
4/9 |
| Q4 2020 |
2021-02-24 |
D |
withdrawn | mixed | contracting |
7/9 |
2/9 |
| Q3 2020 |
2020-11-13 |
C+ |
none | mixed | contracting |
8/9 |
2/9 |
| Q2 2020 |
2020-08-14 |
A |
raised | mixed | contracting |
8/9 |
2/9 |
| Q1 2020 |
2020-05-13 |
D |
withdrawn | mixed | contracting |
7/9 |
3/9 |
| Q4 2019 |
2020-02-21 |
C+ |
maintained | mixed | contracting |
8/9 |
3/9 |
| Q3 2019 |
2019-11-08 |
C+ |
maintained | mixed | mixed |
8/9 |
2/9 |
| Q2 2019 |
2019-08-14 |
D |
lowered | mixed | contracting |
7/9 |
3/9 |
| Q1 2019 |
2019-05-12 |
C |
none | mixed | expanding |
7/9 |
2/9 |
| Q4 2018 |
2019-02-15 |
C+ |
maintained | mixed | contracting |
8/9 |
2/9 |
| Q3 2018 |
2018-11-12 |
C |
maintained | stable | contracting |
7/9 |
3/9 |
| Q2 2017 |
2017-08-12 |
C+ |
none | accelerating | expanding |
7/9 |
3/9 |
| Q3 2016 |
2016-11-11 |
C+ |
lowered | stable | stable |
8/9 |
2/9 |
| Q2 2016 |
2016-08-12 |
C+ |
maintained | stable | stable |
8/9 |
3/9 |
| Q1 2016 |
2016-05-12 |
B |
maintained | stable | contracting |
8/9 |
2/9 |
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← CGI All “C” companies
CGIX →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.